Farallon Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Farallon Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-607,200	Closed	-$10.5M	–	165
2025 Q3	$10.5M	Buy	+607,200	New	+$7.48M	0.04%	74
2023 Q3	–	Sell	-116,000	Closed	-$4.73M	–	173
2023 Q2	$4.73M	Buy	+116,000	New	+$4.7M	0.02%	104
2021 Q1	–	Sell	-225,000	Closed	-$12.2M	–	244
2020 Q4	$12.2M	Buy	+225,000	New	+$8.17M	0.07%	102
2018 Q4	–	Sell	-550,000	Closed	-$15.7M	–	100
2018 Q3	$15.7M	Sell	550,000 -290,000	-35%	-$8.44M	0.09%	75
2018 Q2	$23M	Buy	840,000 +190,000	+29%	+$4.6M	0.14%	61
2018 Q1	$13.7M	Sell	650,000 -490,000	-43%	-$12.1M	0.09%	68
2017 Q4	$21.9M	Buy	+1,140,000	New	+$26.3M	0.18%	53

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Farallon Capital Management's NTLA Position: Q4 2025 in Review

Farallon Capital Management sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 607,200 shares — an estimated $10.5M sold.

Farallon Capital Management first reported a position in NTLA in Q4 2017 and held it in 7 quarters. The position peaked at $23M in Q2 2018. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

Farallon Capital Management reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
Farallon Capital Management sold 607,200 Intellia Therapeutics shares in Q4 2025, an estimated $10.5M.
Farallon Capital Management first reported a position in Intellia Therapeutics in Q4 2017 and held it in 7 quarters.
Farallon Capital Management's Intellia Therapeutics position peaked at $23M in Q2 2018.
292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Farallon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.